

## CASE REPORT

# Production of granulocyte colony-stimulating factor by malignant mesothelioma

T. Rikimaru\*, Y. Ichikawa\*, Y. Ogawa\*, E. Higuchi\*,  
M. Kinoshita\*, K. Oizumi\*, I. Shima\*\*

*Production of granulocyte colony-stimulating factor by malignant mesothelioma. T. Rikimaru, Y. Ichikawa, Y. Ogawa, E. Higuchi, M. Kinoshita, K. Oizumi, I. Shima. ©ERS Journal Ltd 1995.*

**ABSTRACT:** We present the case of a male patient, aged 45 yrs, with malignant mesothelioma producing granulocyte colony-stimulating factor (G-CSF). The diagnosis was established by histopathological examination of the autoptised pleural tissues. Production of G-CSF was confirmed by immunoperoxidase staining, using a specific monoclonal antibody against recombinant G-CSF (rhG-CSF).

*Eur Respir J., 1995; 8, 182-184.*

\*Depts of Medicine, and \*\*Pathology Kurume, University School of Medicine, Kurume, Japan.

Correspondence: T. Rikimaru, First Dept of Internal Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Japan 830

Keywords: Granulocyte colony-stimulating factor, immunohistochemistry, immunoperoxidase staining, malignant mesothelioma.  
Received: April 12 1994, Accepted after revision October 16 1994

Granulocyte colony-stimulating factor (G-CSF) is produced by normal monocytes, macrophages, endothelial cells, fibroblasts and neutrophils. It is also known that some malignant tumours produce G-CSF [1, 2]. However, production of G-CSF by mesothelioma has not previously been reported. We present the first case of G-CSF producing mesothelioma.

### Case Report

A 45 year old male plasterer was admitted to our university hospital because of general fatigue and chest pain. Chest roentgenogram (fig. 1) and computed tomographic (CT) scan disclosed a massive effusion in the right pleural cavity, and an ipsilateral pleural thickening. There was no apparent mass lesion in the lung field.

Peripheral blood analysis revealed a marked leucocytosis of  $51 \times 10^9$  cells·mm<sup>-3</sup>, 93% of the cells being matured neutrophils, slight anaemia (Hb 12.3 g·dl<sup>-1</sup>), and a normal thrombocyte count of  $341 \times 10^9$  cells·mm<sup>-3</sup>. Blood chemistry demonstrated elevated serum levels of lactate dehydrogenase (LDH), 3,830 U·l<sup>-1</sup>, (normal range (N)100~4000 U·l<sup>-1</sup>), alkaline phosphatase (ALP), 18.8 U·l<sup>-1</sup> (N<10 U·l<sup>-1</sup>) and creatine phosphatase (CRP) 19.6 mg·dl<sup>-1</sup> (N<1 mg·dl<sup>-1</sup>). Other hepatic and renal function indicators and tumour markers in the serum remained within normal ranges. Examination of the pleural exudate disclosed an increase in amounts of tumour markers; squamous cell carcinoma related antigen (SCC) 18.2 mg·ml<sup>-1</sup> (N<1.5 mg·ml<sup>-1</sup>), tissue polypeptide antigen (TPA)  $669 \times 10^3$  U·ml<sup>-1</sup> (<1.10 U·ml<sup>-1</sup>), and adenosine deaminase (ADA) 79.2 IU·l<sup>-1</sup> (<50 IU·l<sup>-1</sup>).

A tentative diagnosis of tuberculous pleurisy was made on the basis of the slightly elevated level of ADA (although the tuberculin skin test was negative), and the patient received antituberculous agents. More detailed examination shortly after the start of antituberculous chemotherapy disclosed marked increases in the amounts



Fig. 1. - Chest roentgenogram on admission showing right pleural effusion.

of hyaluronic acid and G-CSF in the pleural effusion, as compared with those in the serum (33.0 vs 0.05 µg·ml<sup>-1</sup> and 11,300 vs 49.7 pg·ml<sup>-1</sup>, respectively). Granulocyte-macrophage colony-stimulating factor (GM-CSF) was not detected in the serum or in the pleural effusion. The patient underwent right thoracotomy and biopsy of the pleural tumour. Microscopic examination of the tissue strongly suggested poorly differentiated malignant mesothelioma, leaving a possibility of large cell carcinoma. Despite intensive antineoplastic chemotherapy, the pleural tumour rapidly increased in size and spread widely over the surface of the pleura. The patient died four weeks after admission.

Autopsy confirmed the absence of primary bronchogenic carcinoma and the replacement of the entire right




Fig. 2. – a) Hyaluronic acid stained with iron colloid stain, and b) digested by hyaluronidase (scale bar=20  $\mu$ m).




Fig. 3. – Immunoperoxidase stain using specific monoclonal antibodies against recombinant granulocyte colony-stimulating factor (rhG-CSF) showed positive staining in the tumour cells. (scale bar=20  $\mu$ m).

pleura by tumour. Micrometastases were found in both lungs, the liver and pancreas. In the autopsied pleural tissues, the deposition of large amounts of hyaluronic acid, which was digested by treatment with hyaluronidase (fig. 2b), was demonstrated by staining the tissues with iron colloid stain (fig. 2a), but not by staining with periodic-acid-Schiff (PAS). Thus, a definite diagnosis of malignant mesothelioma (epithelial type), at Stage IV according to Butchart's pathological staging classification [3], was established. Immunohistochemistry using a specific monoclonal antibody against recombinant G-CSF (rhG-CSF) conjugated with peroxidase [4], clearly demonstrated that the tumour produced a considerable amount of G-CSF (fig. 3).

### Discussion

Colony-stimulating factors (CSFs) include G-CSF, GM-CSF macrophage colony-stimulating factor (M-CSF) and interleukin 3 (IL-3) multi-CSF. Among them, G-CSF induces colony-forming unit-granulocyte/macrophage (CFU-GM) to differentiate into the mature granulocyte, and then to be activated. During the last few years, rhG-CSF has been used for the treatment of neutropaenia due to antitumour chemotherapy. GM-CSF has also been used for this purpose.

In 1977, ASANO *et al.* [1], first reported a case of G-CSF production in lung cancer. Since then, there have been several reports of G-CSF production by bronchogenic carcinomas, especially large cell and squamous cell carcinomas [2, 5, 6].

Tumour progression has usually been rapid, as observed in our patient. The production of G-CSF may be contributory. WOLFGANG *et al.* [7] reported that human haematopoietic growth factors stimulate clonal growth of nonhaematopoietic tumour cells. Such effects are, however, likely to be less important when CSFs are used for therapeutic purposes, since rhG-CSF disappears rapidly after intravenous or subcutaneous administration [8]. In contrast, persistent high levels were observed in our patient.

To our knowledge, there has not been any clinical report on G-CSF production by mesothelioma, although both normal human mesothelial cells and established human malignant mesothelioma cell lines in culture are known to produce haematopoietic colony-stimulating factors, including G-CSF [9, 10].

Dominant clinical manifestations in the present case were fever, and chest pain with pleural effusion, accompanied by marked neutrophilia both in peripheral blood and pleural exudate. These features led to a diagnosis of purulent pleurisy, and later to that of tuberculous pleurisy on the basis of a moderately elevated ADA level in the exudate, before a definite diagnosis of G-CSF production by mesothelioma was established. Care must be taken in similar cases to differentiate malignant effusions from bacterial or tuberculous pleurisy

### References

1. Asano S, Urabe A, Okabe T, *et al.* Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. *Blood* 1977; 49: 845–852.
2. Sato N, Asano S, Ueyama Y, *et al.* Granulocytosis and colony-stimulating activity (CSA) produced by a human squamous cell carcinoma. *Cancer* 1979; 43: 605–610.
3. Butchart EG, Gibbs AR. Pleural mesothelioma. *Curr Opin Oncol* 1990; 2: 352–358.
4. Motojima H, Kobayashi T, Shimane M, Kamachi S, Fukushima M. Quantitative enzyme immunoassay for human granulocyte colony-stimulating factor (G-CSF). *J Immunol Methods* 1989; 118: 187–192.
5. Nagatomo A, Ooike H, Harada A, *et al.* Direct identification of lung cancer cells producing granulocyte colony-stimulating factor with monoclonal anti-G-CSF antibodies. *Intern Med* 1993; 32: 468–471.
6. Shijubo N, Inoue Y, Hirasawa M, *et al.* Granulocyte colony-stimulating factor-producing large cell undifferentiated carcinoma of the lung. *Intern Med* 1992; 31: 277–280.
7. Berder WE, Danhauser-Riedl S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. *Blood* 1989; 73: 80–83.
8. Watari K, Asano S, Shirafuji N, *et al.* Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. *Blood* 1989; 73: 117–122.
9. Demetri GD, Zenie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines *in vitro*. *Blood* 1989; 74: 940–946.
10. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production. *Int J Cancer* 1992; 51: 296–301.